Ultragenyx Pharmaceutical RARE Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -79.5%+16.2pp | -95.7%+35.4pp | -131.1%+47.5pp | -178.6%-70.0pp | |
| Net margin | -85.5%+16.1pp | -101.6%+38.3pp | -139.9%+54.8pp | -194.7%-65.5pp | |
| Efficiency | |||||
| Asset turnover | 0.4×+0.1× | 0.4×+0.1× | 0.3×0.0× | 0.2×0.0× | |
| Liquidity | |||||
| Current ratio | 2.5×+0.1× | 2.4×-0.2× | 2.6×-0.8× | 3.4×-1.3× | |
| Per Share | |||||
| Book value per share | -$0.81-129% | $2.82-24.7% | $3.74-25.7% | $5.03-63.0% | |
| Valuation | |||||
| Market capitalization | $2.22B-42.9% | $3.88B+0.2% | $3.88B+19.4% | $3.25B-43.3% | |
| Price / sales | 3.3×-3.6× | 6.9×-2.0× | 8.9×0.0× | 8.9×-7.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ultragenyx Pharmaceutical's profit margins?
- Ultragenyx Pharmaceutical (RARE) runs a 97.2% gross margin and a -83.8% operating margin, with a -90.9% net margin.
- Where do Ultragenyx Pharmaceutical's ratios come from?
- Every ratio is computed from Ultragenyx Pharmaceutical's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
